In September 2024, we showcased our phase 1 dose escalation study for EBC-129 (NCT05701527) at European Society for Medical Oncology (ESMO) Congress. Further to the ESMO poster presentation, we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (PDAC) cohort in the ongoing dose expansion part of EBC-129’s Phase […]
Guest speaker Adam Gregory from IP firm Mewburn Ellis returns for another webinar with titled “Your Own Prior Art: How to Avoid Shooting Yourself in the Foot!”, Adam will speak on scenarios where your own disclosures can be cited as prior art against future filings. The talk will also cover: The concept of “own prior
Your Own Prior Art: How to Avoid Shooting Yourself in the Foot! Read More »
EDDC is excited to share that we will be collaborating with Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, to bring forward an innovative approach for early drug discovery and development. In this partnership, Partex will initially use its “Asset Exchange” technology platform to identify novel indications for EDDC’s portfolio assets. The parties
EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024. With the initial safety and
EDDC’s Drug Discovery Symposium this year will feature a line-up of esteemed speakers who will share their insights on how Drug Discovery has transformed, and will be transforming through past and future years. Do note that there will also be a closed-door networking session with the speakers after the event, for a limited number
EDDC Annual Drug Discovery Symposium 2024 Read More »
Join us for a webinar organised in partnership with Mewburn Ellis, one of Europe’s top specialist IP firms that has made a name for itself working with numerous local biotechs over the last decade, including MIRXES, Enleofen Bio, Hummingbird Bioscience, and the recently launched VVB Bio. In this seminar, we cover: Identifying Protection Opportunities
Integrated IP Strategy for Platform Technologies and their Products Read More »
EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics! Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific
This event has concluded. Thank you for attending this event. Check out our Events page for more such events! Come join us on 5 Dec 2023 as we plug in to learn more about Boehringer Ingelheim (BI)’s initiatives to support academic research, as well as their partnering, licensing and venture investment interests! Our guest
Exploring the Drug Discovery and Development Landscape with Boehringer Ingelheim Read More »
XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and
EDDC Satellite Seminar – Preclinical in vivo Studies for Drug Discovery and Development Well-designed preclinical in vivo studies are of pivotal importance in the drug development journey and contributes immensely towards a successful IND (Investigational New Drug) approval. In this upcoming session of the EDDC Satellite Seminar series, Associate Director of EDDC’s Translational Sciences
EDDC Satellite Seminar – Preclinical in vivo Studies for Drug Discovery and Development Read More »
